← Leaderboards
Niranjan B Pandey
Asclepix Therapeutics, Inc.
$3,518,519
Attributed
$3,518,519
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2014–19$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$3,518,519 · 6
By mechanism
R44$2,096,994 · 1
R43$1,163,516 · 4
U43$258,009 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Peptides”
- David M Nathan · Massachusetts Institute Of Technology$118,672,444
- John M Lachin · George Washington University$118,672,444
- David Heimbrook · Leidos Biomedical Research, Inc.$91,429,616
- Michael W Weiner · Northern California Institute Res &Educ$78,425,041
- Paul S. Aisen · Cognition Therapeutics, Inc.$69,846,203
- Rolf Apweiler · European Molecular Biology Laboratory$56,677,991
Research focus
PeptidesAngiogenesisPharmaceutical PreparationsVascular Endothelial Growth FactorsDesignSignal TransductionAngiogenic FactorExtravasationBiomimeticsBlood VesselsMedicalLeadPermeabilityNeovascularIntravitreal InjectionGrowth FactorBlindnessChoroidal NeovascularizationOryctolagus CuniculusRetinal DetachmentVisual AcuityMouse ModelNeovascularizationHead
Grant awards (10)
Immunoactivating Peptide AXT201 in Combination with Anti-PD-1 Antibody for Triple-Negative Breast Cancer$299,815
R43 · FY2019 · CA · contact PI
IND-enabling development of a biomimetic peptide drug for macular edema$824,075
R44 · FY2018 · EY · contact PI
Therapeutic peptide for hepatocellular carcinoma$299,983
R43 · FY2018 · CA · contact PI
IND-enabling development of a biomimetic peptide drug for macular edema$107,224
R44 · FY2018 · EY · contact PI
IND-enabling development of a biomimetic peptide drug for macular edema$1,165,695
R44 · FY2017 · EY · contact PI
Development of a mimetic multimodal peptide for the treatment of macular edema$278,133
R43 · FY2015 · EY · contact PI
Long-term anti-angiogenic activity of intravitreal ellipsoid particles for NVAMD$70,982
R43 · FY2015 · EY · contact PI
Targeted nanoparticles to deliver a multimodal peptide to head and neck tumors$258,009
U43 · FY2014 · CA · contact PI
Long-term anti-angiogenic activity of intravitreal ellipsoid particles for NVAMD$189,603
R43 · FY2014 · EY · contact PI
Long-term anti-angiogenic activity of intravitreal ellipsoid particles for NVAMD$25,000
R43 · FY2014 · EY · contact PI